Skip to content

GH-axis

All peptides
Blend

Tesamorelin / Ipamorelin

Also known as: Tesa/Ipa, Tesamorelin + Ipamorelin

Tesamorelin's proven visceral-fat targeting plus Ipamorelin's clean GH pulse in one bedtime injection — visceral fat reduction with broader GH-axis support.

Reviewed 2026-05-27

What it does

Tesamorelin / Ipamorelin pairs a stabilized GHRH analog with a selective GHRP in a fixed-ratio vial. Tesamorelin is the only FDA-approved peptide indication specifically for visceral fat reduction (Egrifta, HIV-associated lipodystrophy) and brings strong human VAT-reduction evidence; Ipamorelin adds a clean ghrelin-pathway GH pulse without cortisol/prolactin elevation. The combination amplifies the GH pulse magnitude beyond Tesamorelin alone.

Dose

Dose
1,000 mcg · 5 days/week (30 units of a 10/5 mg vial)
When
Bedtime1–2 hours before bed, fasted, aligns the GHRH-driven GH pulse with the natural overnight slow-wave-sleep GH window — same logic as the individual components.
How long
6 months on / 2 months off
Site
subcutaneous, before bed, fasted 2+ h
Food
fasted

Need exact volumes? Open the peptide calculator →

⚠ Caution

  • Active malignancy (relative; raised IGF-1 is theoretically permissive of tumor growth)
  • Uncontrolled diabetes / acute glucose dysregulation (GH is counter-regulatory; tesamorelin can transiently elevate fasting glucose)
  • Pituitary surgery, radiation, or trauma — confirm pituitary axis with provider first
  • Severe heart failure; severe respiratory failure or critical illness
  • Pregnancy and breastfeeding
  • Competitive athletes — GH secretagogues are WADA-banned
  • Hypersensitivity to mannitol/excipients or to ipamorelin

Will it work for me?

Establish a baseline (2–3 readings over 1–2 weeks before starting), then track at consistent intervals.

Blood markers
  • Tier 1 — Human RCTIGF-1· by 8 weeks; keep within age-adjusted range — do not chase supraphysiologicPrimary objective marker; the Ipamorelin layer amplifies the pulse but does not change the marker set.
  • Tier 1 — Human RCTTriglycerides· 12–26 weeksImproves alongside VAT reduction in the Tesamorelin trials.
Functional & psychometric
  • Tier 3 — Animal / in vitroWaist circumference + visceral adipose tissue (DEXA)· 12–26 weeksVAT via DEXA was the primary FDA-trial endpoint for Tesamorelin; tracked functionally here.

Your stack

Track this peptide in your protocol — dose, schedule, vials on hand, refill projection. Stays in your browser; no account needed.

Add to my stack

Use this peptide

Cycling

6 months on, 2 months off.

Related peptides

What's in this blend

  • Tesamorelin10 mg/vial· 67%stabilized GHRH analog — proven visceral-fat targeting
  • Ipamorelin5 mg/vial· 33%selective ghrelin/GHSR-1a agonist — clean GH pulse
Reconstitution & storage
VialBAC waterConcentrationShelf life
15 mg3 mL1.5 mg (1 mg Tesa + 0.5 mg Ipa) per 30 units (10/5 mg blend)10 days

Standard blend vial is 10 mg Tesamorelin + 5 mg Ipamorelin. Reconstitute a 10/5 mg vial with 3 mL BAC water for 1.5 mg total peptide per 30 units; the vial lasts ~10 days at 30 units/day.

Storage. Lyophilized: refrigerate, long-term stable. Reconstituted: refrigerate 2–8 °C, use within ~10 days.

Open the peptide calculator →

Nasal delivery

Not suitable for nasal delivery. GH secretagogues require SQ injection for a reliable pituitary pulse; no validated nasal protocol.

Monitoring & questions

Reported side effects
  • Injection site reactions
  • Transient joint pain / arthralgia
  • Mild fluid retention / peripheral edema
  • Tingling or carpal-tunnel-type symptoms at higher GH exposure
  • Vivid dreams (Ipamorelin)
Biomarkers Juno tracks

Reference

How it works

Tesamorelin sets the GHRH 'permission' for GH release (sustained GHRH-receptor stimulation with proven visceral-fat targeting); Ipamorelin pulls the ghrelin-pathway trigger for a clean pulse. Together they produce a larger GH pulse and downstream IGF-1 rise. The combination is used clinically on the strength of the individual peptides; no combination-specific RCT exists.

EvidenceTier 2 — Human observational

Tiers are per indication. The same molecule can be Tier 1 for one use and Tier 4 for another — the tier reflects published literature, not community framing.

Visceral adipose tissue (VAT) reduction

Tier 2high confidence

Tesamorelin has Tier 1 human RCT evidence for VAT reduction in HIV-associated lipodystrophy (Falutz 2007/2010, FDA-approved). For the off-label non-HIV/general-population use that this blend targets, the tier is 2 (extrapolating from the approved indication per the evidence-tier rules); the Ipamorelin layer and the combination itself have no dedicated RCT.

Body composition with muscle-preservation signal

Tier 3medium confidence

The combination is claimed to give a stronger muscle-preservation signal than Tesamorelin alone, but this specific combination claim has no controlled human data — Tier 3.

GH/IGF-1 axis support (sleep, recovery, anti-aging)

Tier 3medium confidence

Both components raise GH/IGF-1 (mechanistic, with per-component human PK/PD), but the longevity/recovery framing for this blend has no combination RCT and stays Tier 3.

Citations (2)
  1. [1]
    Metabolic effects of a growth hormone-releasing factor in patients with HIV
    Falutz J, Allas S, Blot K, et al. · New England Journal of Medicine · 2007 · PMID 18057339
    Phase 3 RCT evidence that Tesamorelin reduces visceral fat (and triglycerides) — the human anchor for the VAT indication.
    View source
  2. [2]
    Ipamorelin, the first selective growth hormone secretagogue
    Raun K, Hansen BS, Johansen NL, et al. · European Journal of Endocrinology · 1998 · PMID 9849822
    Characterization of Ipamorelin's clean GH pulse — the second component anchor.
    View source